Tirzepatide for PCOS: what the TikTok journey skips over

What did @arinashleyyy actually say?

Honestly? Not much, medically speaking. The transcript is almost entirely song lyrics, which means the substantive information here comes from the caption, not the spoken content. She disclosed starting at "2.5mg for 4 weeks" before moving up to "5mg this week," and framed the video around her fear of needles and hesitation before starting tirzepatide. The hashtags tie this to PCOS and GLP-1 use. That is the full clinical picture she offered.

This matters because a lot of GLP-1 content on TikTok does the same thing: the real claims live in captions and hashtags while the video itself is more lifestyle documentation. Viewers absorb the framing without a single verifiable statement to scrutinize. In this case, the dosing progression she described is consistent with standard titration schedules, which is worth noting.

Does the science back this up?

The dosing schedule she described, 2.5mg followed by an uptitration to 5mg, matches the FDA-approved starting protocol for tirzepatide exactly. This is not a coincidence or personal experimentation. It is the labeled starting dose.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants lost an average of 20.9% of body weight at the highest dose over 72 weeks. More relevant to her PCOS hashtag, a 2023 analysis in the Journal of Clinical Endocrinology and Metabolism found GLP-1 receptor agonists improved insulin sensitivity and androgen profiles in women with PCOS, though tirzepatide-specific PCOS trial data is still limited. Her needle anxiety disclosure is also clinically relevant: fear of self-injection is a documented barrier to GLP-1 adherence (Polinski et al., 2019, Patient Preference and Adherence).

What did they get wrong (or right)?

She did not get the dosing wrong. The 2.5mg to 5mg progression is precisely what the prescribing information calls for. Give credit where it is due.

What she did not address, and what the PCOS hashtag implies without stating, is the mechanism. Tirzepatide is not approved specifically for PCOS. It is approved for weight management and type 2 diabetes. The metabolic benefits that may help PCOS symptoms, reduced insulin resistance, lower androgen levels, improved ovulatory function, are downstream effects of weight loss and improved metabolic health, not a direct treatment action. Framing tirzepatide as a PCOS treatment without that distinction is a soft mislead, even if unintentional. The hashtag does that work quietly. Viewers with PCOS may interpret her experience as a template without understanding that results depend heavily on individual metabolic profiles, and that a prescriber should be directing this, not a TikTok comment section.

What should you actually know?

A few things that the caption-plus-song-lyric format cannot tell you. First, the 2.5mg starting dose exists specifically to reduce gastrointestinal side effects. It is a tolerability dose, not a therapeutic one. Most clinical benefit in trials was seen at 10mg and 15mg. Second, tirzepatide requires a valid prescription and medical oversight. Third, compounded tirzepatide, which has circulated widely during shortage periods, is not the same as FDA-approved Zepbound or Mounjaro. Potency, sterility, and inactive ingredients differ. Do not assume equivalency.

For PCOS specifically: the evidence that GLP-1 class drugs improve hormonal and metabolic markers in PCOS is growing but not yet enough to call it a standard of care. A 2022 review in Reproductive Biology and Endocrinology found meaningful improvements in BMI, fasting insulin, and testosterone in women with PCOS using GLP-1 agonists, but most studies were small and short. Talk to an endocrinologist or a prescriber with PCOS experience before treating someone else's TikTok journey as a protocol.

The bottom line

This video is a personal update, not medical guidance, and it should be read as exactly that. The dosing she described is accurate to label. The PCOS framing is understandable but imprecise. Needle anxiety as a barrier to starting is real and worth normalizing. What is missing is any discussion of supervision, individual variability, or the difference between correlation and treatment. Weekly update videos build a narrative that feels like evidence. It is not.